Kategorie
Absolute Antibody oferuje szereg rekombinowanych przeciwciał przeciwko antygenom wirusowym. Przeciwciała początkowo wytworzono za pomocą klasycznej technologii hybrydomy, technologii prezentacji fagowej lub sekwencjonowania (unieśmiertelnionych) komórek B od zakażonych pacjentów.
| Nazwa przeciwciała [klon] | Reaktywność | Zastosowanie |
| Anti-3pk [3p-8-1] | Human | WB |
| Anti-4-1BB [BBK2 ] | Human | antagonist, Blocking, IP, FC, IF, IHC |
| Anti-A14 [BB5.2] | Vaccinia virus | IP, WB, IF |
| Anti-AMIGO-1 [AC27] | Mouse | ELISA, IF, IHC |
| Anti-AMIGO-1 [AC50] | Mouse | ELISA, IF, IHC |
| Anti-ASCL1 [SC72.2] | Human | ELISA, IHC |
| Anti-avian infectious bronchitis virus Nucleoprotein [C5P1] | avian infectious bronchitis virus | WB, ELISA |
| Anti-Bovine Coronavirus [BCoV1/1] | Bovine coronavirus | EIA, neutralizing, ELISA, IF |
| Anti-Bovine coronavirus [SF-3E4] | Bovine coronavirus | neutralising, WB, ELISA |
| Anti-Bovine Herpesvirus gD [BoScFv] | Bovine Herpesvirus-1 | WB, Block, ELISA, IF |
| Anti-Canarypox Virus [CNPV-5A11] | Canarypox virus | WB, ELISA, IF |
| Anti-Canine Parvovirus [scFv] | canine parvovirus | NTRL, ELISA |
| Anti-Capsid protein VP3 [VHH-12B] | Poliovirus | cryo EM, ELISA |
| Anti-Capsid protein VP3 [VHH-7A] | Poliovirus | cryo EM, ELISA |
| Anti-Capsid protein VP3 [VHH-7B] | Poliovirus | cryo EM, ELISA |
| Anti-CCR5 [ST6] | rhesus macaque, Human | depleting, SPR, ELISA, FC |
| Anti-CD205 [DEC-205] | Mouse | vaccination |
| Anti-CD25 [7D4] | Mouse | depleting, FC |
| Anti-CD4 [5A8] | Human | RIA, WB, ELISA, IHC |
| Anti-CD4 [EDU-2 (B486)] | Human | FC, IF, IHC |
| Anti-CD5 [OX-19] | Rat | inhibit, WB, FC, IHC |
| Anti-CD81 [CD81K04] | Human | crystallisation, Neutralisation, FC |
| Anti-Cedar virus F [19E 7] | Cedar henipavirus (Cedar virus) | IP, WB |
| Anti-Cedar virus G [11D5] | Cedar henipavirus (Cedar virus) | IP |
| Anti-Cedar virus G [14F3] | Cedar henipavirus (Cedar virus) | IP, WB |
| Anti-cFos [C1-82] | Human | WB, ELISA, IF, IHC |
| Anti-cFos [C1-84] | Human | WB, ELISA, IF, IHC |
| Anti-cFos [C2-58] | Human | WB, ELISA, IF, IHC |
| Anti-cFos [C2-66] | Human | WB, ELISA, IF, IHC |
| Anti-cFos [S1-54] | Human | WB, ELISA, IF, IHC |
| Anti-cFos [S1-71] | Human | WB, ELISA, IF, IHC |
| Anti-CMV [EIV-15] | Cytomegalovirus | NTRL, ELISA |
| Anti-CMV coat protein [6A1] | Cucumber mosaic virus | WB, ELISA |
| Anti-CMV glycoprotein gB [HCMV37] | CMV | ICC, NTRL, ELISA, IF, IHC-Fr |
| Anti-Coat protein [DDF-RuV1] | Rubella Virus | neutralize, ELISA |
| Anti-Coat protein [DDF-RuV2] | Rubella Virus | neutralize, ELISA |
| Anti-Covid-19 & SARS-CoV Nucleocapsid [1C7C7] | SARS-CoV, SARS-CoV-2 | WB, ELISA, FC, IHC |
| Anti-Covid-19 & SARS-CoV Nucleoprotein [CR3009 (03-009)] | SARS-CoV, SARS-CoV2 | ELISA, IF |
| Anti-Covid-19 & SARS-CoV Nucleoprotein [CR3018 (03-018)] | SARS-CoV, SARS-CoV2 | ELISA, IF |
| Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022] | SARS-CoV-2 (COVID-19) & SARS Coronavirus | crystallography, NTRL, SPR, ELISA, IF |
| Anti-CPV capsid [A3B10 (MAb 8)] | canine parvovirus, feline panleukopenia virus | IP, NTRL, ELISA |
| Anti-CPV capsid [Clone 2] | canine parvovirus | ELISA |
| Anti-CymMV Coat protein [11A12F5] | Cymbidium mosaic virus | ELISA |
| Anti-Cytomegalovirus (CMV) gH glycoprotein [MSL-109] | CMV | NTRL |
| Anti-DENV-2 E protein [4G2] | Dengue Virus, Flavivirus group, Zika Virus | functional assay, ELISA, IF, IHC |
| Anti-DI/DII domain of Dengue E protein [DV18] | Dengue Virus | NTRL, ELISA |
| Anti-DI/DII domain of Dengue E protein [DV78] | Dengue Virus | NTRL, ELISA |
| Anti-DIII domain of Dengue E protein (DENV-1 and DENV-3) [DV63] | Dengue Virus | NTRL, ELISA |
| Anti-DIII domain of Dengue E protein [DV10] | Dengue Virus | NTRL, ELISA |
| Anti-dsRNA [1D3] | Virus | WB, ELISA, IHC |
| Anti-dsRNA [9D5 ] | Virus | WB, ELISA, IHC |
| Anti-dsRNA [J2] | Species independent | IP, ELISA, EM, IF, IHC |
| Anti-dsRNA/ssRNA [P6] | Species independent | fucntional assay, ELISA |
| Anti-E protein [13D6] | Tick-borne encephalitis virus | neutralization, ELISA, IHC |
| Anti-E protein [14D5] | Tick-borne encephalitis virus | crystallization, in vitro, in vivo, neutralization, SPR, ELISA |
| Anti-E protein [Mab 4.2] | Louping ill virus, Tick-borne encephalitis virus | Cristallization, in vivo, neutralizing, SPR, ELISA, IF |
| Anti-E protein [T025] | Tick-borne encephalitis virus | crystallization, in vivo, neutralizing, ELISA, IF |
| Anti-E-protein DIII (ABDE) [ZV-2] | Zika Virus | crystallization, SPR, FC |
| Anti-E-protein DIII (C-C’) [ZV-48] | Zika Virus | crystallization, NTRL, SPR, FC |
| Anti-E-protein DIII (C-C’) [ZV-64] | Zika Virus | crystallization, NTRL, SPR, FC |
| Anti-E-protein DIII (LR) [ZV-67] | Zika Virus | crystallization, NTRL, SPR, WB, FC |
| Anti-E2 A domain [F5] | Human Venezuelan Equine Encephalitis Virus | crystallization, NTRL |
| Anti-E2 B domain [3b4c-4] | Human Venezuelan Equine Encephalitis Virus | crystallization, NTRL, ELISA |
| Anti-E2 protein [Chk265] | Alphaviruses, Chikungunya | crystallization, NTRL, ELISA, FC, IF |
| Anti-Ebola GP [13F6-1-2] | Ebola Virus | functional assay, neutralizing, SPR, WB, ELISA |
| Anti-Ebola GP [h-13F6] | EBOV (Zaire) | IP, SPR, ELISA |
| Anti-Ebola Nucleoprotein [KZ51] | Ebola Virus (Zaire, Ivory Coast, Reston, Sudan) | IP, WB, ELISA, IF |
| Anti-Ebola surface glycoprotein [KZ52] | Ebola (Zaire) | crystallization, IP, NTRL, IF |
| Anti-Ebola virus VP35 protein; [6c5] | Zaire ebolavirus | IP, Western blot, IF |
| Anti-Envelope glycoprotein Gc [A5] | Hantavirus | crystallization, SPR |
| Anti-Envelope protein [ZKA64] | Zika Virus | enhance, NTRL, ELISA, FC |
| Anti-Envelope protein [ZKA78] | Dengue Virus, Zika Virus | enhance, NTRL, ELISA, FC |
| Anti-Envelope protein domain III [POWV-80] | Powassan virus | crystallography, neutralizing, ELISA, FC |
| Anti-F glycoprotein [12B2] | Nipah virus | functional assay, neutralize |
| Anti-Feline Calicivirus; [1D7] | Feline calicivirus | NTRL, ELISA |
| Anti-FGF12/FHF1 [N94/17] | Rat, Human, Mouse | IP, IHC |
| Anti-FGF13/FHF2 [N91/27.1] | mouse, rat, Human | WB |
| Anti-FHV-1 [JH2] | Feline Herpes Virus | cat diagnostics, cat therapeutics, neutralising |
| Anti-Flavivirus group antigen [D1-4G2-4-15 (4G2)] | Dengue Virus, Flaviviridae, West Nile Virus, Yellow Fever Virus, Zika Virus | IHC-P, NTRL, WB, ELISA, FC, IF |
| Anti-GABA(B)R [N93A/49.2] | Rat, Human, Mouse | IP, PLA, IF |
| Anti-Gephyrin [GC1] | Human | WB, ELISA, IF, IHC |
| Anti-Gephyrin [GC52] | Human | WB, ELISA, IF, IHC |
| Anti-Gephyrin [GC92] | Human | WB, ELISA, IF, IHC |
| Anti-Gephyrin [GS41] | Human | WB, ELISA, IF, IHC |
| Anti-Gephyrin [GS8] | Human | WB, ELISA, IF, IHC |
| Anti-GFP [N86/38.1] | Aequorea victoria | IP, IF, IHC |
| Anti-Ghana Virus F [7C11-LY] | Ghana virus | IP, ELISA |
| Anti-Ghana Virus G [10C4-LY] | Ghana virus | IP, WB, ELISA |
| Anti-Ghana Virus G [10D5-LY] | Ghana virus | IP, WB, ELISA |
| Anti-Glycoprotein [MR78] | Ebola Virus, Marburg Virus | neutralize, ELISA |
| Anti-Glycoprotein B of HSV [Fd79] | Herpes Simplex Virus | NTRL, FC, IF |
| Anti-Glycoprotein Complex [37.7H] | Lassa virus | crystallography, NTRL, WB, ELISA |
| Anti-Glycoprotein D of HSV [Fd138-80] | Herpes Simplex Virus | NTRL, FC, IF |
| Anti-glycoprotein E [19/1786] | Tick-borne encephalitis virus | Cryo-EM, IP, Neurtalization, WB, ELISA |
| Anti-Glycoprotein E1 [IGH526 (4805, 48G5C4)] | Hepatitis C virus (HCV) | functional assay, neutralize, ELISA, FC, IF |
| Anti-Glycoprotein E2 [19B3] | Hepatitis C virus (HCV) | functional assay, neutralizing, ELISA |
| Anti-Glycoprotein E2 [212.1.1] | Hepatitis C virus (HCV) | functional assay, neutralization, ELISA, FC |
| Anti-Glycoprotein E2 [AP33] | Hepatitis C virus (HCV) | functional assay, IP, neutralize, Block, ELISA |
| Anti-Glycoprotein E2 [HC-11] | Hepatitis C virus (HCV) | IP, neutralize, ELISA, FC, IF |
| Anti-Glycoprotein E2 [HC-1AM] | Hepatitis C virus (HCV) | neutralize, ELISA, FC |
| Anti-Glycoprotein E2 [HC33.1] | Hepatitis C virus (HCV) | neutralize, WB, ELISA |
| Anti-Glycoprotein E2 [HC84.26.5D (HC26AM)] | Hepatitis C virus (HCV) | IP, neutralize, ELISA |
| Anti-Glycoprotein H [A13-d6.3] | pseudorabies virus (PrV) | crystalize, immunostaining, neutralize |
| Anti-Glycoprotein H [MAb 5] | HCMV | ELIS, IP, RIA |
| Anti-GP1 [GD01] | Junin virus (JUNV) | crystallize, neutralize, ELISA |
| Anti-HA [8H5] | Influenza A Virus (several subtypes) | Hemagglutination inhibition test;, NTRL, ELISA |
| Anti-HA [AV.C4] | H5N1 Influenza A Virus | NTRL, WB, ELISA |
| Anti-HA [AV.D1] | H5N1 Influenza A Virus | NTRL, ELISA |
| Anti-HA [AV.G4] | H5N1 Influenza A Virus | WB, ELISA |
| Anti-HA [CR6261] | Influenza A Virus (several subtypes) | NTRL, therapeutic |
| Anti-HA [CR8020] | Influenza A Virus (several subtypes) | NTRL, therapeutic, FC |
| Anti-HA [FB75] | Influenza A Virus (several subtypes) | NTRL, ELISA |
| Anti-HA [FC41] | Influenza A Virus (several subtypes) | ELISA |
| Anti-HA [FE17] | Influenza A Virus (several subtypes) | ELISA |
| Anti-HAV IRES domain V [HAVx] | Hepatitis A Virus | ELISA |
| Anti-HBeAg [E6] | Hep B | cross-competition assay, crystallization, Mab: RIA, serum protein electrophoresis. Fab |
| Anti-HBsAg [5C3] | Hepatitis B Virus | RIA |
| Anti-HBsAg [F124 scFv] | Hepatitis B Virus | ELISA |
| Anti-HCMV [8F9] | Human Cytomegalovirus | IP, neutralize, WB, ELISA, FC |
| Anti-HCMV gB [5A6] | Human cytomegalovirus (HCMV) | IP, Neutralisation, FC, IF |
| Anti-HCMV gB [HCMV37] | Human Cytomegalovirus | IP, NTRL, ELISA, IF |
| Anti-HCMV gH [HCMV16] | Human Cytomegalovirus | IP, NTRL, ELISA, IF |
| Anti-HCV E1E2 complex [AR4A (N4)] | Hepatitis C virus (HCV) | IP, neutralize, therapeutic, ELISA, FC |
| Anti-HCV IRES junction IIIabc [HCV2] | Hepatitis C virus | therapeutic, ELISA |
| Anti-HCV NS3 Protein [Hfab-aNS3] | Hepatitis C | helicase assay, ICC, ELISA |
| Anti-Hemagglutinin [17/9] | Influenza A virus | |
| Anti-hemagglutinin H1 [3978] | Influenza B virus | functional assay, ELISA, FC |
| Anti-hemagglutinin H1 [5589] | Influenza A virus | functional assay, ELISA, FC |
| Anti-hemagglutinin H1 [7665] | Influenza A virus | functional assay, ELISA, FC |
| Anti-hemagglutinin H3 [1664] | Influenza A virus | functional assay, ELISA, FC |
| Anti-Hendra and Nipah virus G [48D3] | Hendra henipavirus (Hendra virus, HeV), Nipah henipavirus (Nipah virus, NiV) | IP, WB |
| Anti-Hendra and Nipah virus G [5B1] | Hendra henipavirus (Hendra virus, HeV), Nipah henipavirus (Nipah virus, NiV) | IP, neutralizing |
| Anti-Hendra and Nipah virus G [7B7] | Hendra henipavirus (Hendra virus, HeV), Nipah henipavirus (Nipah virus, NiV) | IP, neutralizing |
| Anti-Hepatitis A virus capsid [R10] | Hepatitis A Virus | crystallisation, Neutralisation, ELISA |
| Anti-His tag [4C9] | Species independent | epitope tag, WB, ELISA |
| Anti-His tag [H343] | Species independent | epitope tag, Purification, ELISA |
| Anti-His tag [H7219] | Species independent | epitope tag, Purification, ELISA |
| Anti-HIV capsid protein p24 [13B5] | HIV | SPR, ELISA |
| Anti-HIV capsid protein p24 [CB4-1] | HIV | ELISA |
| Anti-HIV GP41 [2E7 (L92E7)] | HIV-1 | NTRL, ELISA |
| Anti-HIV-1 GP120 [0.5B] | HIV-1 | IP, NTRL, FC |
| Anti-HIV-1 gp120 [447-D] | HIV-1 (Human immunodeficiency virus 1) | functional assays, neutralizing, WB, ELISA, IF |
| Anti-HIV-1 gp120 [694-D] | HIV-1 (Human immunodeficiency virus 1) | functional assays, neutralizing, WB, ELISA, IF |
| Anti-HIV-1 GP120 [b12 (MT12)] | HIV-1 | neutralize, therapeutic, ELISA |
| Anti-HIV-1 GP120 [HGD65] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HGN194] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HGZ1] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HJ16] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HR10] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HR12] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [PGT124] | HIV-1 | functional assay, neutralize, ELISA |
| Anti-HIV-1 GP120 [VRC03] | HIV-1 | neutralize, SPR, ELISA |
| Anti-HIV-1 GP120 [X5] | HIV-1 | functional assay, neutralization, WB, ELISA, FC |
| Anti-HIV-1 GP120 [YZ18] | HIV-1 | ELISA, NTRL |
| Anti-HIV-1 GP120 [YZ23] | HIV-1 | ELISA, NTRL |
| Anti-HIV-1 GP41 [HGF24] | HIV-1 | NTRL |
| Anti-HIV-1 GP41 [HK20] | HIV-1 | NTRL |
| Anti-HN Protein [1A6] | Sendai Virus | Hemagglutination inhibition, Neutralisation, IF |
| Anti-HPV16E6 & HPV18E6 [C1P5] | Human papilloma virus | IP, WB, IHC |
| Anti-HSV-1 VP5 [6F10-D2-G2] | Herpes simplex | functional assays, IP, WB, ELISA, IF |
| Anti-Human Rhinovirus 14 [Fab17-IA] | Human Rhinovirus 14 | Neutralize; |
| Anti-iC3b [5D2] | Human, Mouse | IP, ELISA, IHC |
| Anti-IFNa 2b [scFv 17] | Human | ELISA |
| Anti-IFNA 8 [α8#139] | Human | Immunoaffinity chromatography, NTRL, RIA, WB, ELISA |
| Anti-IFNA 8 [α8Y36-2] | Human | RIA, WB, ELISA |
| Anti-IFNAR-1 [64G12] | Human | confocal microscopy, inhibit, IP, NTRL, WB, ELISA, FC, IF |
| Anti-infectious bursal disease virus [CRAb154] | infectious bursal disease virus | IP, ELISA |
| Anti-infectious bursal disease virus VP2 [CRAb 88] | very virulent infectious bursal disease virus (CS89) | IP, ELISA |
| Anti-influenza [2-8C] | Influenza A virus nucleoprotein (NP) | neutralisation assays, virus titration/quantification, WB, ELISA, IF, IHC |
| Anti-influenza [2-12C] | Influenza A virus hemagglutinin glycoprotein (HA) | hemagglutination inhibition test, microneutralization assays, virus titration, ELISA, IF |
| Anti-influenza [3-10B] | Influenza B virus nucleoprotein (NP) | neutralisation assays |
| Anti-influenza [T1-3B] | Influenza A virus hemagglutinin glycoprotein (HA) | hemagglutination inhibition test, microneutralization assays, virus titration, ELISA, IF |
| Anti-Influenza A HA [FLD127] | H5N1 Influenza A Virus | NTRL, RIA, ELISA |
| Anti-Influenza A HA [FLD20] | H5N1 Influenza A Virus | NTRL |
| Anti-Influenza A HA [FLD21] | H5N1 Influenza A Virus | NTRL |
| Anti-Influenza A HA [FLD84] | H5N1 Influenza A Virus | NTRL, RIA, ELISA |
| Anti-Influenza A HA [FLD93] | H5N1 Influenza A Virus | NTRL |
| Anti-Influenza A HA [HA] | Influenza A Virus (several subtypes) | ELISA |
| Anti-Influenza A nucleoprotein [aNP-VHH1] | Influenza A | crystallography, IP, EM, FC |
| Anti-Influenza A virus NS1 [NS1-23-1] | Influenza A virus | IP, WB |
| Anti-JEV virions (E/PrM) [TJE12B02] | Japanese Encephalitis Virus | IP, NTRL, ELISA |
| Anti-La Crosse virus, G1 envelope glycoprotein [807.15] | La Crosse Bunyavirus | IP, neutralising assays, viral serology, WB, ELISA, FC |
| Anti-La Crosse virus, G1 envelope glycoprotein [807.31] | La Crosse Bunyavirus | IP, neutralising assays, viral serology, WB, ELISA, FC |
| Anti-LAM [CS-35] | Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium bovis | ELISA;, WB, FC, IF |
| Anti-LDL receptor [12G4] | Hamster, Rat, Human, Mouse | Block, ELISA, FC, IHC |
| Anti-LMP1 [S12] | Epstein-Barr virus | IB, IP, WB, ELISA, FC, IHC |
| Anti-LMP2A [14B7] | Epstein-Barr virus | IB, IP, WB, ELISA, IF |
| Anti-M13 bacteriophage [E1] | M13 phage | WB, ELISA, FC, IHC |
| Anti-Malin [N85/18.1] | Human | IP, WB, IHC |
| Anti-Marburg virus nucleoprotein [sdAb 4] | Marburg virus (MARV) | cross-linking, crystallography, ELISA |
| Anti-Matrix Protein [E10] | Influenza A virus | WB, ELISA, FC, IHC |
| Anti-MERS-CoV Spike protein [1F8] | MERS Coronavirus | NTRL |
| Anti-MERS-CoV Spike protein [3A1] | MERS Coronavirus | NTRL |
| Anti-MERS-CoV Spike protein [3B12] | MERS Coronavirus | NTRL |
| Anti-MERS-CoV Spike Protein [4c2] | MERS-CoV | crystallization, NTRL, ELISA |
| Anti-MERS-CoV Spike protein [M14D3] | MERS Coronavirus | NTRL |
| Anti-MESD [N88/12.1] | Rat, Human, Mouse | IP, WB, IHC |
| Anti-Mojiang Virus F [3C4-LY] | Mojiang henipavirus (Mojiang virus, MojV) | IP, ELISA |
| Anti-Mojiang Virus F [4G5-LY] | Mojiang henipavirus (Mojiang virus, MojV) | IP, WB, ELISA |
| Anti-Mojiang Virus G [10G2-LY] | Mojiang henipavirus (Mojiang virus, MojV) | IP, ELISA |
| Anti-Mojiang Virus G [6E5-LY] | Mojiang henipavirus (Mojiang virus, MojV) | IP, ELISA |
| Anti-Monkeypox Virus [VACV-5C7] | Monkeypox virus | ELISA, IF |
| Anti-Murine leukemia virus p30 gag capsid polypeptide [R187] | Murine leukemia virus | IP, IF |
| Anti-N9 Neuraminidase [NC41 ] | Influenza | crystallisation |
| Anti-Neutralizing Epitope [ZKA185] | Zika Virus | NTRL |
| Anti-Nipah and Hendra G [nAH1.3] | Hendra virus, Nipah virus | neutralizing |
| Anti-Nipah virus F F1 [5G7] | Nipah henipavirus (Nipah virus, NiV) | IP, WB |
| Anti-Nipah virus F F2 [11F10] | Nipah henipavirus (Nipah virus, NiV) | IP, WB |
| Anti-Nipah virus F F2 [6D3] | Nipah henipavirus (Nipah virus, NiV) | IP, WB |
| Anti-Nipah virus F Site I [16C2] | Nipah henipavirus (Nipah virus, NiV) | IP |
| Anti-Nipah virus F Site II [4C9] | Nipah henipavirus (Nipah virus, NiV) | IP |
| Anti-Nipah virus F Site IV [1E 11] | Nipah henipavirus (Nipah virus, NiV) | IP |
| Anti-Nipah virus F1 [13G5] | Nipah henipavirus (Nipah virus, NiV) | IP, WB |
| Anti-Norovirus capsid protein VP1 [A1227] | Norovirus | ELISA |
| Anti-Norovirus GII.4 [NVB43.9] | Norovirus | NTRL, Block |
| Anti-Norovirus GII.4 P domain [A1431] | Norovirus | neutralize, Block, ELISA |
| Anti-Norovirus GII.4 VP1 [8E1] | Norovirus | neutralize, ELISA |
| Anti-Norovirus P domain [Nano-27] | Norovirus | crystallography, ITC, neutralisation assay, ELISA |
| Anti-Norovirus P domain [Nano-4] | Norovirus | crystallography, ITC, neutralisation assay, ELISA |
| Anti-Notch 1 [WC613] | Human | IP, ELISA, FC |
| Anti-Notch 1 [WC75] | Human | IP, ELISA, FC |
| Anti-NP [JS08] | SARS-CoV-2 | SPR, WB, ELISA |
| Anti-NP [JS16] | SARS-CoV-2 | SPR, WB, ELISA |
| Anti-NS1 [22NS1 ] | West Nile Virus | crystallography, NTRL, FC |
| Anti-NS1 [ZKA35] | Zika Virus | Blockade-of-Binding ELISA, BOB ELISA, Competition ELISA, ELISA |
| Anti-Orthopoxviruses [VACV-5B1] | Orthopoxviruses | Immunogold electron microscopy, IP, WB, ELISA, FC, IF |
| Anti-p35 protein of Orthopoxvirus [1A] | Orthopoxvirus | WB, ELISA |
| Anti-Parvovirus [MAbE] | canine parvovirus, feline panleukopenia virus | IP, Neutralisation, RIA, ELISA, EM |
| Anti-peptides (neutralizing epitope) [Clone 36] | Influenza A (H3N2) | ELISA |
| Anti-PERV [7C4] | Porcine Endogenous Retrovirus | neutralize, WB, ELISA |
| Anti-PERV [A5] | Porcine Endogenous Retrovirus | WB |
| Anti-PERV p27 [D2] | Porcine Endogenous Retrovirus | WB |
| Anti-Poxvirus L1 Protein [Fab 7d11] | Poxviruses | crystallization, PRNT, ELISA |
| Anti-pre- and post-fusion conformation of HRSV F protein [RSB15] | Respiratory Syncytial Virus (RSV) | NTRL, IF |
| Anti-pre- and post-fusion conformation of HRSV F protein [RSB16] | Respiratory Syncytial Virus (RSV) | NTRL, IF |
| Anti-pre-fusion conformation of HRSV F protein [RSB20] | Respiratory Syncytial Virus (RSV) | NTRL, IF |
| Anti-pre-fusion conformation of HRSV F protein [RSB43] | Respiratory Syncytial Virus (RSV) | NTRL, IF |
| Anti-PRSV coat protein [9G2D3] | Papaya ringspot virus | ELISA |
| Anti-Rabies Virus 67kDa protein [EP5G3] | Rabies Virus | IP, NTRL, WB, ELISA |
| Anti-Rabies Virus 67kDa protein [Fab094] | Rabies Virus | IP, NTRL, WB, ELISA |
| Anti-Rabies Virus 67kDa protein [GD2D12] | Rabies Virus | IP, NTRL, WB, ELISA |
| Anti-Rabies Virus Glycoprotein [A11] | Rabies virus (Pasteur strain) | WB, ELISA |
| Anti-Rabies Virus Glycoprotein [C12] | Rabies virus (CVS-11) | ELISA |
| Anti-Rabies Virus Glycoprotein [R16E5] | Rabies Virus | NTRL, WB, ELISA |
| Anti-RRV E2 [D7] | Ross River Virus | labelling, FC |
| Anti-RSV [RSHZ19 (Felvizumab)] | RSV | functional, ELISA |
| Anti-RSV G protein [131-2G] | Respiratory Syncytial Virus (RSV) | therapeutic, ELISA |
| Anti-RSV G protein [CB002.5] | Respiratory Syncytial Virus (RSV) | neutralize, ELISA |
| Anti-S protein (RBD) [STE90-C11] | SARS-CoV-2 | biolayer interferometry, crystallography, in vitro inhibition, in vitro neutralization, in vivo protection, therapeutic, ELISA |
| Anti-S2 domain [S2A3] | MERS | SPR, ELISA, IF |
| Anti-Saint Louis encephalitis virus envelope glycoprotein [6B6C-1] | Saint Louis encephalitis virus | immunoblot, IP, ELISA |
| Anti-SAPAP2 [SS88] | Rat | WB, ELISA, IF, IHC |
| Anti-SARS-CoV Nucleoprotein [N18] | SARS Coronavirus | ELISA |
| Anti-SARS-CoV S glycoprotein [11A] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [1B5] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [256] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [4D4] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [4G2] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [4S1] | SARS Coronavirus | ELISA, IF |
| Anti-SARS-CoV S glycoprotein [5D3] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [5E4] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [6B1] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [A11] | SARS Coronavirus | WB, ELISA, IF |
| Anti-SARS-CoV S glycoprotein [F26G10] | SARS Coronavirus | NTRL, ELISA, IF |
| Anti-SARS-CoV S glycoprotein [F26G19] | SARS Coronavirus | NTRL, WB, ELISA, IF |
| Anti-SARS-CoV S glycoprotein [F26G9] | SARS Coronavirus | NTRL, ELISA, IF |
| Anti-SARS-CoV S glycoprotein [Lsc18] | SARS Coronavirus | WB, ELISA, IF |
| Anti-SARS-CoV S glycoprotein [S109] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S110] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S124] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S215] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S217] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S222] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S223] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S225] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S226] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S227] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S228] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S230] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [S231] | SARS Coronavirus | NTRL, ELISA |
| Anti-SARS-CoV S glycoprotein [Ssc35] | SARS Coronavirus | WB, ELISA, IF |
| Anti-SARS-CoV-2 and SARS-CoV nucleocapsid [mBG17] | SARS Coronavirus | WB, ELISA, IF |
| Anti-SARS-CoV-2 nucleocapsid [mBG86] | SARS-CoV-2 | WB, ELISA, IF |
| Anti-SARS-CoV-2 Spike protein (RBD monomer) [2B-E7-C9] | SARS Coronavirus 2 (SARS-Cov-2) | ELISA |
| Anti-SARS-CoV-2 Spike protein (RBD monomer) [2B-G10-A1] | SARS Coronavirus 2 (SARS-Cov-2) | ELISA |
| Anti-SEB [6D3] | Staphylococcus aureus | ELISA, WB, Inhibit, Block |
| Anti-Spike protein [EY6A] | SARS Coronavirus 2 (SARS-Cov-2) | NTRL, Surface Plasmon Resonance, therapeutic, ELISA, IF |
| Anti-Spike protein [MR17 ] | SARS Coronavirus 2 (SARS-Cov-2) | biolayer interferometry, FACS, NTRL, therapeutic, ELISA |
| Anti-Spike protein [MR3] | SARS Coronavirus 2 (SARS-Cov-2) | biolayer interferometry, FACS, NTRL, therapeutic, ELISA |
| Anti-Spike protein [Sb23] | SARS Coronavirus 2 (SARS-Cov-2) | biolayer interferometry, NTRL, ELISA |
| Anti-Spike protein [SR4] | SARS Coronavirus 2 (SARS-Cov-2) | biolayer interferometry, FACS, NTRL, therapeutic, ELISA |
| Anti-Spike protein [Ty1] | SARS Coronavirus 2 (SARS-Cov-2) | biolayer interferometry, inhibit, NTRL, ELISA, FC, IF |
| Anti-Spike Protein (RBD) [CV30] | SARS Coronavirus 2 | neutralize, therapeutic, ELISA, FC |
| Anti-Spike protein (RBD) [Sb#14] | SARS Coronavirus 2 (SARS-Cov-2) | grating-coupled interferometry, inhibition, therapeutics, ELISA |
| Anti-Spike protein (RBD) [Sb#15] | SARS Coronavirus 2 (SARS-Cov-2) | grating-coupled interferometry, inhibition, therapeutics, ELISA |
| Anti-Spike protein (RBD) [Sb#16] | SARS Coronavirus 2 (SARS-Cov-2) | grating-coupled interferometry, inhibition, therapeutics, ELISA |
| Anti-Spike protein (RBD) [Sb#42] | SARS Coronavirus 2 (SARS-Cov-2) | grating-coupled interferometry, inhibition, therapeutics, ELISA |
| Anti-Spike protein (RBD) [Sb#45] | SARS Coronavirus 2 (SARS-Cov-2) | grating-coupled interferometry, inhibition, therapeutics, ELISA |
| Anti-Spike protein (RBD) [Sb#68] | SARS Coronavirus 2 (SARS-Cov-2) | grating-coupled interferometry, inhibition, therapeutics, ELISA |
| Anti-Spike protein [18F4] | SARS Coronavirus 2 (SARS-Cov-2) | functional assay, SPR, Block, ELISA |
| Anti-Spike protein [4A8] | SARS Coronavirus 2 (SARS-Cov-2) | functional assay, neutralizing, ELISA, FC |
| Anti-Spike Protein [CV1] | SARS Coronavirus 2 | neutralize, therapeutic, ELISA, FC |
| Anti-Spike protein [D70678-5521-S2] | SARS Coronavirus 2 (SARS-Cov-2) | functional assay, SPR, ELISA |
| Anti-Tetanus toxoid [F13] | Clostridium tetani | NTRL, WB, ELISA |
| Anti-TGEV Coronavirus Spike glycoprotein [1AF10] | TGEV coronavirus | NTRL, RIA, WB, ELISA |
| Anti-V5 epitope tag [SV5-P-K] | Paramyxovirus Simian Virus 5 | IP, RIA, WB, ELISA, IF, IHC-Fr |
| Anti-Vaccinia A13 protein [11F7] | Monkeypox virus, Orthopoxvirus, Vaccinia virus, variola virus | neutralize, SPR, WB, ELISA, IF |
| Anti-Vaccinia A33 glycoprotein [A2C7] | Vaccinia virus | neutralization, IF |
| Anti-Vesicular stomatitis virus nucleoprotein N [VHH-1004] | Vesicular stomatitis virus (VSV) | LUMIER assays, transcription assays, FC |
| Anti-VP1 protein [EBB-C1975-B5] | BK virus, Human polyomavirus 1 | NTRL, ELISA |
| Anti-VP1 protein [NEG447A] | BK virus, Human polyomavirus 1 | ELISA |
| Anti-VP2 [8F5] | Human rhinovirus type 2 | NTRL, WB, IP, IHC |
| Anti-VP35 [H3] | Marburg Virus | crystallography, inhibition, ELISA |
| Anti-VSV-M [23H12] | Vesicular stomatitis Indiana virus | WB, IF |
| Anti-VSV-N [10G4] | Vesicular stomatitis Indiana virus | WB |
| Anti-WNV Envelope protein [9E2] | West Nile Virus | NTRL, WB |
| Anti-WNV Envelope protein DI-DII [E53] | West Nile Virus | crystallography, NTRL |
| Anti-Yellow Fever Virus [2D12] | Yellow Fever Virus | functional assay, RIA, ELISA, FC, IF |
| Anti-ZIKV E domain II [SMZAb2] | Zika Virus | neutralisation assays, therapeutic, ELISA |
| Anti-ZIKV E domain III [SMZAb1] | Zika Virus | neutralisation assays, therapeutic, ELISA |
| Anti-ZIKV E domain III [SMZAb5] | Zika Virus | neutralisation assays, therapeutic, ELISA |
| Anti-ZIKV E domain III [Z004] | DENV1 virus, Zika Virus | crystallography, neutralisation assays, ELISA |
| Anti-ZIKV soluble envelope protein [z23] | Zika Virus | Block |
Aktualne promocje
ZAPRASZAMY DO ZAPOZNANIA SIĘ Z PRZECIWCIAŁAMI CYTOMETRYCZNYMI FIRMY ELABSCIENCE.
SZEROKI WYBÓR FLUOROCHROMÓW POZWALA NA DOKŁADNE DOPASOWANIE PRZECIWCIAŁ DO SPECYFIKI BADAŃ
OBECNIE WSZYSTKIE PRODUKTY TEJ KATEGORII DOSTĘPNE SĄ Z RABATEM 10%
